A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen

Trial Profile

A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Celecoxib (Primary) ; Ibuprofen; Naproxen
  • Indications Musculoskeletal pain; Osteoarthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms PRECISION
  • Sponsors Pfizer
  • Most Recent Events

    • 26 Jul 2017 Results of post hoc subgroup analyses published in the American Journal of Medicine
    • 13 Nov 2016 Primary endpoint (The first occurrence of cardiovascular death,(APTC composite endpoint)) has been met,according to the results published in the New England Journal of Medicine.
    • 13 Nov 2016 Results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top